JPWO2021237110A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021237110A5
JPWO2021237110A5 JP2022571133A JP2022571133A JPWO2021237110A5 JP WO2021237110 A5 JPWO2021237110 A5 JP WO2021237110A5 JP 2022571133 A JP2022571133 A JP 2022571133A JP 2022571133 A JP2022571133 A JP 2022571133A JP WO2021237110 A5 JPWO2021237110 A5 JP WO2021237110A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition according
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527775A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033693 external-priority patent/WO2021237110A1/en
Publication of JP2023527775A publication Critical patent/JP2023527775A/ja
Publication of JPWO2021237110A5 publication Critical patent/JPWO2021237110A5/ja
Pending legal-status Critical Current

Links

JP2022571133A 2020-05-22 2021-05-21 Il-4r阻害剤の投与により好酸球性食道炎を処置する方法 Pending JP2023527775A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063029085P 2020-05-22 2020-05-22
US63/029,085 2020-05-22
US202063066705P 2020-08-17 2020-08-17
US63/066,705 2020-08-17
US202063071264P 2020-08-27 2020-08-27
US63/071,264 2020-08-27
US202063088147P 2020-10-06 2020-10-06
US63/088,147 2020-10-06
US202063121088P 2020-12-03 2020-12-03
US63/121,088 2020-12-03
US202163144939P 2021-02-02 2021-02-02
US63/144,939 2021-02-02
EP21315068 2021-04-21
EP21315068.3 2021-04-21
PCT/US2021/033693 WO2021237110A1 (en) 2020-05-22 2021-05-21 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Publications (2)

Publication Number Publication Date
JP2023527775A JP2023527775A (ja) 2023-06-30
JPWO2021237110A5 true JPWO2021237110A5 (enExample) 2024-05-28

Family

ID=76444669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571133A Pending JP2023527775A (ja) 2020-05-22 2021-05-21 Il-4r阻害剤の投与により好酸球性食道炎を処置する方法

Country Status (11)

Country Link
US (1) US20250154267A2 (enExample)
EP (1) EP4153300A1 (enExample)
JP (1) JP2023527775A (enExample)
KR (1) KR20230015965A (enExample)
CN (1) CN115768516A (enExample)
AU (1) AU2021277398A1 (enExample)
BR (1) BR112022022235A2 (enExample)
CA (1) CA3174431A1 (enExample)
IL (1) IL298257A (enExample)
MX (1) MX2022014440A (enExample)
WO (1) WO2021237110A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
US20230340601A1 (en) * 2022-04-26 2023-10-26 Regeneron Pharmaceuticals, Inc. Transcriptome Analysis For Treating Inflammation
MA71395A (fr) * 2022-07-08 2025-04-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r
TW202502820A (zh) 2023-03-27 2025-01-16 美商再生元醫藥公司 藉由投予il—4r拮抗劑治療嗜酸性球性胃腸炎之方法
WO2025221247A1 (en) * 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
JP6013915B2 (ja) * 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
EA037960B1 (ru) * 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
TWI777515B (zh) * 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
IL315556A (en) * 2017-08-04 2024-11-01 Regeneron Pharma Methods for treating active eosinophilic esophagitis
WO2019165138A1 (en) * 2018-02-21 2019-08-29 Adare Development I, L.P. Methods of managing eosinophilic esophagitis
KR102880460B1 (ko) * 2018-06-14 2025-11-06 아지노모토 가부시키가이샤 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
EP3878868B1 (en) 2018-11-09 2024-10-09 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof

Similar Documents

Publication Publication Date Title
JPWO2021237110A5 (enExample)
Zervas et al. An algorithmic approach for the treatment of severe uncontrolled asthma
JP6306588B2 (ja) Il−4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN105517570B (zh) 通过施用il-4r拮抗剂治疗鼻息肉症的方法
JP6861630B2 (ja) Il−4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
TWI814575B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
JP2016523863A5 (enExample)
CN115768516A (zh) 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
JP2022160685A5 (enExample)
IL316408A (en) A safe and effective method for treating psoriasis with a specific anti-IL23 antibody
US20200206227A1 (en) Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof
Chehade et al. Treatment of eosinophilic esophagitis: diet or medication?
JP2020502261A5 (enExample)
KR20240052871A (ko) 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
JP2024016237A5 (enExample)
Stokes et al. Rationale for new treatments aimed at IgE immunomodulation
JPWO2019222055A5 (enExample)
JP2025072440A5 (enExample)
JPWO2017172771A5 (enExample)
CN1612751A (zh) 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗
JPWO2021026205A5 (enExample)
Moawad et al. Eosinophilic esophagitis
JP2021138743A (ja) Il−4rアンタゴニストの投与により鼻茸を処置する方法
JP2020073525A5 (enExample)
JP2020529434A5 (enExample)